Ignite Creation Date:
2024-05-06 @ 2:49 PM
Last Modification Date:
2024-10-26 @ 1:38 PM
Study NCT ID:
NCT04439305
Status:
WITHDRAWN
Last Update Posted:
2020-07-20
First Post:
2020-06-18
Brief Title:
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes MATCH-Subprotocol X
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Refractory Plasma Cell Myeloma |
| Advanced Lymphoma |
| Advanced Malignant Solid Neoplasm |
| Hematopoietic and Lymphoid Cell Neoplasm |
| Refractory Lymphoma |
| Refractory Malignant Solid Neoplasm |
Keywords: